Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

NNC6022-0001

Phase 1Small molecule

1

Indications

1

Total Trials

0

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiometabolic DiseaseCompleted

Cardiometabolic DiseasePhase 1

Completed

Clinical

Trials by Indication[1]

Cardiometabolic Disease1 trial

A First Human Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Target Engagement of Single Doses of NNC6022-0001 in Healthy Adults.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06336005·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NNC6022-0001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NNC6022-0001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NNC6022-0001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Novo Nordisk

Related News